Patents by Inventor Mark Rogers-Evans

Mark Rogers-Evans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BACE1 inhibitors
    Patent number: 9920072
    Abstract: The present invention provides a compound of formula (I), having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: March 20, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Didier Rombach, Thomas Woltering
  • 2,2,2-trifluoroethyl-thiadiazines
    Patent number: 9896438
    Abstract: The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: February 20, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Lilli Anselm, Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Haap Wolfgang, Jens-Uwe Peters, Thomas Woltering, Ulrike Obst Sander, Mark Rogers-Evans
  • BACE1 INHIBITORS
    Publication number: 20170334930
    Abstract: The present invention provides a compound of formula (I), having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: October 30, 2015
    Publication date: November 23, 2017
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Didier Rombach, Thomas Woltering
  • Piperazine thiazole derivatives useful in the treatment of tauopathies such as Alzheimer's disease
    Patent number: 9808456
    Abstract: The present invention relates to a compound of formula (IA), wherein G1 is lower alkyl; lower alkyl substituted by one or more halogens; cycloalkyl; tetrahydropyran-4-yl; phenethyl; phenethyl substituted by one or more halogens; phenoxymethyl; phenoxymethyl substituted by one or more halogens; benzyloxyethyl; benzyloxy-ethyl substituted by one or more halogens; or is —NR2R3; R2 is hydrogen or lower alkyl; R3 is lower alkyl; tetrahydropyran-4-yl; —CH2-cycloalkyl; or cycloalkyl optionally substituted by lower alkyl substituted by one or more halogens; or R2 and R3 form together with the N-atom to which they are attached a heterocycloalkyl group with 4 or 5 carbon atoms, which is optionally substituted by one or more substituents selected from halogen; or lower alkyl substituted by one or more halogens; X is —CH2— or —(CH2)2—; Ar is phenyl or pyridinyl; R4 is halogen; lower alkyl; lower alkyl substituted by one or more halogens; or lower alkoxy; n is 1 or 2; or to a pharmaceutically active salt thereof, to a ste
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: November 7, 2017
    Assignee: REMYND NV
    Inventors: Gerard Griffioen, Giuseppe Cecere, Matthias Nettekoven, Katrien Princen, Hasane Ratni, Mark Rogers-Evans, Walter Vifian
  • 2,7-diazaspiro[3.5]nonane compounds
    Patent number: 9750745
    Abstract: The present invention relates to a compound of formula (I) or a stereoisomer, enantiomer, racemic, or tautomer thereof, Formula (I), wherein R1, R3, R4, L1, L2, L3, L4, and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: September 5, 2017
    Assignee: REMYND NV
    Inventors: Gerard Griffioen, Bart De Taeye, Katrien Princen, Koen De Witte, Emilie Blanche, Hasane Ratni, Mark Rogers-Evans
  • 2,2,2-TRIFLUOROETHYL-THIADIAZINES
    Publication number: 20170226091
    Abstract: The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: August 12, 2015
    Publication date: August 10, 2017
    Inventors: Lilli ANSLEM, Bjoern BARTELS, Cosimo DOLENTE, Wolfgang GUBA, Haap WOLFGANG, Jens-Uwe PETERS, Thomas WOLTERING, Ulrike OOBST SANDER, Mark ROGERS-EVANS
  • NOVEL TRIAZOLO[4,5-D]PYRIMIDINES
    Publication number: 20170204103
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 and n are defined as in the description and in the claims. The compound of formula (I) can be for treating.
    Type: Application
    Filed: April 4, 2017
    Publication date: July 20, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Matthias Nettekoven, Mark Rogers-Evans, Sebastien Schmitt, Benjamin James Stenton
  • Pyrazol derivatives
    Patent number: 9694012
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: July 4, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • RADIOLABELED CANNABINOID RECEPTOR 2 LIGAND
    Publication number: 20170166534
    Abstract: The present invention relates to a compound of formula (I) wherein R1 is defined as in the description and in the claims. The compound of formula (I) can be used as radiolabeled ligand.
    Type: Application
    Filed: February 27, 2017
    Publication date: June 15, 2017
    Applicants: Hoffmann-La Roche Inc., EIDGENÖSSISCHE TECHNISCHE HOCHSCHULE ZÜRICH, UNIVERSITÄT ZÜRICH
    Inventors: Simon M. Ametamey, Juergen Fingerle, Luca Gobbi, Uwe Grether, Ahmed Haider, Thomas Hartung, Linjing Mu, Leo Nicholls, Mark Rogers-Evans, Christoph Ullmer
  • 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS
    Publication number: 20170157137
    Abstract: The present invention relates to a compound of formula (I) or a stereoisomer, enantiomer, racemic, or tautomer thereof, Formula (I), wherein R1, R3, R4, L1, L2, L3, L4, and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 8, 2017
    Applicant: REMYND NV
    Inventors: Gerard Griffioen, Bart De Taeye, Katrien Princen, Koen De Witte, Emilie Blanche, Hasane Ratni, Mark Rogers-Evans
  • 2,7-diazaspiro[3.5]nonane compounds
    Patent number: 9617264
    Abstract: The present invention relates to a compound of formula (I) or a stereoisomer, enantiomer, racemic, or tautomer thereof, Formula (I), wherein R1, R3, R4, L1, L2, L3, L4, and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: April 11, 2017
    Assignee: REMYND NV
    Inventors: Gerard Griffioen, Bart De Taeye, Katrien Princen, Koen De Witte, Emilie Blanche, Hasane Ratni, Mark Rogers-Evans
  • OXADIAZOLE COMPOUNDS
    Publication number: 20170073319
    Abstract: The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1, R2, R3, L1, L2, L3, L4, L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.
    Type: Application
    Filed: March 17, 2015
    Publication date: March 16, 2017
    Applicant: REMYND NV
    Inventors: Gerard GRIFFIOEN, Bart DE TAEYE, Katrien PRINCEN, Koen DE WITTE, Emilie BLANCHE, Hasane RATNI, Matthias NETTEKOVEN, Mark ROGERS-EVANS
  • Triazolo[4,5-D]pyrimidine derivatives
    Patent number: 9593123
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: March 14, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Matthias Nettekoven, Mark Rogers-Evans, Stephan Roever, Sebastien Schmitt, Atsushi Kimbara
  • Pyrrolo[2,3-D]pyrimidine derivatives as CB2 receptor agonists
    Patent number: 9580435
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: February 28, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • NOVEL PYRAZOL DERIVATIVES
    Publication number: 20170035769
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: October 24, 2016
    Publication date: February 9, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: UWE GRETHER, ATSUSHI KIMBARA, MATTHIAS NETTEKOVEN, FABIENNE RICKLIN, STEPHAN ROEVER, MARK ROGERS-EVANS, TANJA SCHULZ-GASCH
  • 2,7-DIAZASPIRO[3.5]NONANE COMPOUNDS
    Publication number: 20170015665
    Abstract: The present invention relates to a compound of formula (I) or a stereoisomer, enantiomer, racemic, or tautomer thereof, Formula (I), wherein R1, R3, R4, L1, L2, L3, L4, and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.
    Type: Application
    Filed: March 17, 2015
    Publication date: January 19, 2017
    Applicant: REMYND NV
    Inventors: Gerard Griffioen, Bart De Taeye, Katrien Princen, Koen De Witte, Emilie Blanche, Hasane Ratni, Mark Rogers-Evans
  • BACE1 inhibitors
    Patent number: 9540397
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: January 10, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Philipp Cueni, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Walter Vifian, Thomas Woltering
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20160376262
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: September 9, 2016
    Publication date: December 29, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Luca Gobbi, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20160376237
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: September 9, 2016
    Publication date: December 29, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Luca Gobbi, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Roger Slavik
  • Pyridine derivatives
    Patent number: 9522886
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: December 20, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Beat Frei, Luca Gobbi, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch